Suppr超能文献

肝素与人抗凝血酶III的结合激活了赖氨酸236处的选择性化学修饰。赖氨酸107、赖氨酸125和赖氨酸136位于抗凝血酶III的肝素结合位点内。

Binding of heparin to human antithrombin III activates selective chemical modification at lysine 236. Lys-107, Lys-125, and Lys-136 are situated within the heparin-binding site of antithrombin III.

作者信息

Chang J Y

机构信息

Pharmaceuticals Research Laboratories, Ciba-Geigy Ltd., Basel, Switzerland.

出版信息

J Biol Chem. 1989 Feb 25;264(6):3111-5.

PMID:2492530
Abstract

A new water-soluble color reagent, 4-N,N-dimethylaminoazobenzene-4'-isothiocyano-2'-sulfonic acid (S-DABITC), was used to identify lysine residues of antithrombin III which participate in the binding of heparin. Antithrombin, modified with S-DABITC in the presence and absence of low molecular weight heparin (Mr 5000) was reduced, carboxymethylated, and digested with trypsin. The digest was analyzed by high-performance liquid chromatography and monitored at 465 nm. In the absence of heparin, four major colored peptides (T1, T2, T3, and T4) were identified. When antithrombin was preincubated with heparin (2-fold by weight), followed by S-DABITC modification, the recovery of peptide T4 remained unchanged, but the recoveries of T1, T2, and T3 were reduced by 93, 86, and 98%, respectively. In addition, a new colored peptide, TA, appeared. Amino acid sequencing of peptides T1, T2, T3, and TA localized S-DABITC modification sites as Lys-136, Lys-125, Lys-107, and Lys-236, respectively. Thus, binding of heparin to human antithrombin diminished S-DABITC modification at Lys-107, Lys-125, and Lys-136, but at the same time enhanced S-DABITC modification at Lys-236. This phenomenon was further characterized by varying the molar ratio of heparin/antithrombin (from 0.04 to 20). The shielding of Lys-125 and Lys-136 was inversely proportional to the activation of Lys-236. At a heparin/antithrombin molar ratio of 1, the extent of shielding of Lys-125 and Lys-136 and the unmasking of Lys-236 were 25-33%. This shielding-unmasking effect correlated with enhanced antithrombin inhibition of thrombin. We conclude that Lys-107, Lys-125, and Lys-136 are situated within the heparin-binding site of human antithrombin and that binding of heparin to antithrombin causes a conformational change of antithrombin that leads to the exposure of Lys-236 for S-DABITC modification.

摘要

一种新型水溶性显色试剂,4-N,N-二甲基氨基偶氮苯-4'-异硫氰酸-2'-磺酸(S-DABITC),被用于鉴定抗凝血酶III中参与肝素结合的赖氨酸残基。在有和没有低分子量肝素(Mr 5000)存在的情况下,用S-DABITC修饰抗凝血酶,然后进行还原、羧甲基化,并用胰蛋白酶消化。消化产物通过高效液相色谱分析,并在465nm处进行监测。在没有肝素的情况下,鉴定出四种主要的显色肽段(T1、T2、T3和T4)。当抗凝血酶与肝素(重量比2倍)预孵育,然后进行S-DABITC修饰时,肽段T4的回收率保持不变,但T1、T2和T3的回收率分别降低了93%、86%和98%。此外,出现了一种新的显色肽段TA。对肽段T1、T2、T3和TA进行氨基酸测序,将S-DABITC修饰位点分别定位为Lys-136、Lys-125、Lys-107和Lys-236。因此,肝素与人抗凝血酶的结合减少了Lys-107、Lys-125和Lys-136处的S-DABITC修饰,但同时增强了Lys-236处的S-DABITC修饰。通过改变肝素/抗凝血酶的摩尔比(从0.04到20)进一步表征了这种现象。Lys-125和Lys-136的屏蔽与Lys-236的活化呈反比。在肝素/抗凝血酶摩尔比为1时,Lys-125和Lys-136的屏蔽程度以及Lys-236的暴露程度为25%-33%。这种屏蔽-暴露效应与抗凝血酶对凝血酶抑制作用的增强相关。我们得出结论,Lys-107、Lys-125和Lys-136位于人抗凝血酶的肝素结合位点内,并且肝素与抗凝血酶的结合导致抗凝血酶的构象变化,从而导致Lys-236暴露以进行S-DABITC修饰。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验